These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36836593)

  • 21. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
    Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
    Tang Q; Pan D; Xu C; Chen L
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.
    Wang HK; Xu XH; Wang SM; Zhang HY
    Transl Cancer Res; 2024 Jan; 13(1):173-190. PubMed ID: 38410201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development.
    Li RQ; Wang W; Yan L; Song LY; Guan X; Zhang W; Lian J
    Front Oncol; 2022; 12():973712. PubMed ID: 36226063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.
    Chen Z; Wang X; Yan Z; Zhang M
    Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.
    Zhuang H; Tang C; Lin H; Zhang Z; Chen X; Wang W; Wang Q; Tan W; Yang L; Xie Z; Wang B; Chen B; Shang C; Chen Y
    Cell Oncol (Dordr); 2024 Aug; 47(4):1205-1220. PubMed ID: 38315287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development.
    Chen Y; Jiang N; Chen M; Sui B; Liu X
    Front Cell Dev Biol; 2022; 10():1064754. PubMed ID: 36467412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development.
    Chen X; Zhang T; Zhai X; Wan Z; Ge M; Liu C; Tan M; Xu D
    Front Immunol; 2022; 13():1037808. PubMed ID: 36405755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
    Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
    Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
    Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
    Front Immunol; 2021; 12():755401. PubMed ID: 34917077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Novel Tumor Antigens and the Immune Landscapes of Bladder Cancer Patients for mRNA Vaccine Development.
    Wang G; Gao Y; Chen Y; Wang K; Zhang S; Li G
    Front Oncol; 2022; 12():921711. PubMed ID: 35814377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.
    Liao W; Shi Z; Tang H; Wu T; Zhang C; He Y; Zou R; Wang L
    J Oncol; 2022; 2022():6851026. PubMed ID: 36072981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
    Liu T; Zhang M; Sun D
    Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine.
    Sun Z; Jing C; Zhan H; Guo X; Suo N; Kong F; Tao W; Xiao C; Hu D; Wang H; Jiang S
    Front Immunol; 2023; 14():1097472. PubMed ID: 36761744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
    Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
    Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Tumor Antigens and Immune Subtypes for the Development of mRNA Vaccines and Individualized Immunotherapy in Soft Tissue Sarcoma.
    Wu C; Duan Y; Gong S; Osterhoff G; Kallendrusch S; Schopow N
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
    Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
    Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
    Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
    Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Novel Tumor Pyroptosis-Related Antigens and Pyroptosis Subtypes for Developing mRNA Vaccines in Pancreatic Adenocarcinoma.
    Lin Q; Liang L; Wang Q; Wang X; You Y; Rong Y; Zhou Y; Guo X
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.